重组人血小板生成素与白细胞介素-11治疗非小细胞肺癌化疗后血小板减少症临床观察  

Clinical observation of recombinant human thrombopoietin and interleukin-11 for thrombocytopenia in patients with non-small cell lung cancer after chemotherapy

作　　者：张芳芳[1] 董文杰[1] 王丽萍[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052

出　　处：《中华实用诊断与治疗杂志》2014年第4期339-341,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：青年科学基金项目(81302120);河南省医学科技攻关计划项目(201303038);河南省科技厅基础与前沿项目(122300410155)

摘　　要：目的探讨重组人血小板生成素(recombinant human thrombopoietin,rhTPO)与重组白细胞介素-11(recombinant human interleukin-11,rhIL-11)治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)化疗后血小板减少症效果。方法 64例NSCLC经吉西他滨联合顺铂化疗后血小板计数≤75×109/L患者,随机分为治疗组与对照组各32例;治疗组皮下注射rhTPO 15 000u/d,对照组皮下注射rhIL-11 1.5mg/d,均1次/d,连续应用14d,观察2组治疗效果和不良反应发生情况。结果治疗组与对照组治疗期间血小板最低值分别为(51.46±13.70)×109/L和(36.24±8.24)×109/L,血小板最高值分别为(221.30±90.30)×109/L和(136.60±70.40)×109/L,2组比较差异有统计学意义(P<0.05);治疗组血小板计数<50×109/L的持续时间和升高至≥100×109/L所需时间较对照组分别平均缩短了2.9d和2.5d(P<0.05);治疗期间治疗组与对照组输注血小板例数分别为1例和6例;不良反应发生率治疗组(9.3%)低于对照组(37.5%)(P<0.05)。结论 rhTPO治疗NSCLC患者化疗后血小板减少疗效优于rhIL-11,不良反应轻。Objective To explore the therapeutic effect of recombinant human thrombopoietin （rhTPO） and recombinant human interleukin-ll （rhIL-11） on gemcitabine and cisplatin-induced thrombocytopenia in patients with non-small cell lung cancer （NSCLC）. Methods Sixty-four NSCLC patients with platelet75 X 10^9/L after chemotherapy with gemeitabine and cisplatin were randomly divided into treatment group and control group, with 32 patients in each group. Treatment group received subcutaneous injection of rhTPO 15 000 u/d and control group was given subcutaneous injection of rhIL-11 1.5 mg/d, once per day, for totally 14 days. The therapeutic effect and adverse reaction were observed and compared. Results The mean minimal platelet count and the mean maximal platelet count were （51.46 ± 13.70） X 109/L and （221. 30 ± 90. 30） X 10^9/L in treatment group, significantly higher than those in control group （（36.24±8.24）X10^9/L, （136.60±70.40）X10^9/L） （P〈0.05）. In treatment group, the time of platelet count to 50X 10^9/L and the recovery time of platelet count to 100X 10^9/L were 2.9 and 2.5 days shorter than those in control group （P〈0.05）. There were 1 and 6 patients receiving platelet transfusion in treatment group and control group respectively （P〈0.05）. The incidence of adverse reaction was 9.3% in treatment group, significant lower than that in control group （37.5 %） （P〈0.05）. Conclusions rhTPO is superior to rhIL-11 for thrombocytopenia in NSCLC patients after chemotherapy, with mild adverse reactions.

关 键 词：非小细胞肺癌 重组人血小板生成素 重组白细胞介素-11 血小板减少 

分 类 号：R734.2[医药卫生—肿瘤]